El-Fattah Mohamed Abd
Department of Internal Medicine, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
J Clin Transl Hepatol. 2017 Jun 28;5(2):83-91. doi: 10.14218/JCTH.2017.00015. Epub 2017 May 14.
Non-Hodgkin lymphoma (NHL) of the liver is a rare lymphoid malignancy, accounting for less than 1% of extranodal lymphomas. I conducted an analysis of the U.S Surveillance, Epidemiology, and End Results (SEER) database to evaluate the histological subtypes and the survival outcomes of 785 cases with hepatic NHL between 1973 and 2012. There were 785 of 312 459 cases with NHL had a first primary hepatic NHL (0.25%). Of the total 785 cases, the median age at diagnosis was 61 years (range 3-95 years) and male-female ratio of 1.7:1. The most common subtype was diffuse large B cell lymphoma (63.2%). In all patients, the median overall survival (OS) was 33 months (95%CI, 22-48 months). The 5-year OS rate for indolent B-cell NHLs was 62%, compared with 44% for an aggressive B-cell NHLs and 42% for T-cell NHLs. The median OS improved from 19 months in patients diagnosed in a period 1996-2000 to 60 months when diagnosed between 2006 and 2012 ( < .001). In a multivariable Cox regression analysis, the age ≥80 years (adjusted hazard ratio [aHR] 3.21, < .001), male gender (aHR 1.26, = .02), Black race (aHR, 1.70, < .001), and T-cell NHL variants (aHR 1.73, = .03) were unfavourable prognostic factors. NHL of the liver comprises about 0.3% of all NHLs and survival was improved in the recent calendar period.
肝脏非霍奇金淋巴瘤（NHL）是一种罕见的淋巴恶性肿瘤，占结外淋巴瘤的比例不到1%。我对美国监测、流行病学和最终结果（SEER）数据库进行了分析，以评估1973年至2012年间785例肝脏NHL患者的组织学亚型和生存结果。在312459例NHL患者中，有785例首次原发性肝脏NHL（0.25%）。在总共785例病例中，诊断时的中位年龄为61岁（范围3 - 95岁），男女比例为1.7:1。最常见的亚型是弥漫性大B细胞淋巴瘤（63.2%）。所有患者的中位总生存期（OS）为33个月（95%CI，22 - 48个月）。惰性B细胞NHL的5年OS率为62%，侵袭性B细胞NHL为44%，T细胞NHL为42%。中位OS从1996 - 2000年诊断的患者的19个月提高到2006年至2012年诊断的患者的60个月（P <.001）。在多变量Cox回归分析中，年龄≥80岁（调整后风险比[aHR] 3.21，P <.001）、男性（aHR 1.26，P =.02）、黑人种族（aHR，1.70，P <.001）和T细胞NHL变异型（aHR 1.73，P =.03）是不良预后因素。肝脏NHL约占所有NHL的0.3%，近期生存率有所提高。
